Here we investigated the MCL1 inhibitor S63845, the MEK-inhibitor trametinib, and the MDM2- inhibitor HDM201 in AML cell lines and patient cells in order to identify a potentially effective treatment for AML patients unfit for intensive chemotherapy. This evidence concerns the gene MAP2K7 and acute myeloid leukemia.